Zacks Research Issues Pessimistic Forecast for BDX Earnings

Becton, Dickinson and Company (NYSE:BDX) – Equities research analysts at Zacks Research reduced their FY2027 earnings per share (EPS) estimates for shares of Becton, Dickinson and Company in a report issued on Monday, December 16th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will earn $16.68 per share for the year, down from their previous forecast of $16.75. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.77 by $0.04. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The firm’s revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.42 EPS.

Other research analysts have also issued research reports about the stock. Evercore ISI raised their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price target for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Finally, StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average price target of $283.50.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $223.83 on Wednesday. The stock has a 50-day moving average price of $230.06 and a two-hundred day moving average price of $233.27. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $249.89. The company has a market capitalization of $64.71 billion, a PE ratio of 37.68, a P/E/G ratio of 1.64 and a beta of 0.41. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.86%. The ex-dividend date is Monday, December 9th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 70.03%.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 4,483 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the transaction, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. This represents a 15.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.31% of the stock is owned by company insiders.

Institutional Trading of Becton, Dickinson and Company

Large investors have recently made changes to their positions in the company. WR Wealth Planners LLC boosted its stake in Becton, Dickinson and Company by 1.4% during the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock valued at $696,000 after purchasing an additional 42 shares during the last quarter. Clear Creek Financial Management LLC grew its holdings in Becton, Dickinson and Company by 5.1% during the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after buying an additional 44 shares in the last quarter. Sound Income Strategies LLC raised its position in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the last quarter. Central Pacific Bank Trust Division lifted its stake in Becton, Dickinson and Company by 22.5% during the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 45 shares in the last quarter. Finally, Tompkins Financial Corp boosted its holdings in Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.